Anlon Healthcare IPO Review, Details, Date, Price, GMP, Allotment
The primary market is buzzing with a fresh opportunity for investors as Anlon Healthcare Limited launches its Initial Public Offering (IPO). This Rajkot-based company, specializing in high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), is set to raise funds to fuel its ambitious expansion plans. This blog post provides a detailed and comprehensive review of the Anlon Healthcare IPO, covering all the essential aspects you need to know before considering an investment.
About Anlon Healthcare Limited
Established in 2013, Anlon Healthcare has carved a niche for itself in the highly specialized and quality-driven pharmaceutical and specialty chemicals sector. The company focuses on manufacturing high-purity pharmaceutical intermediates, which serve as key starting materials for APIs. Their diverse product portfolio also includes nutraceuticals, personal care, and veterinary ingredients. Anlon Healthcare is one of the few manufacturers of Loxoprofen Sodium Dihydrate in India, an API used to treat pain and inflammation. With a robust R&D focus and adherence to global standards (IP, BP, EP, JP, USP), the company has built a strong foundation and a growing client base.
Anlon Healthcare IPO Details
The Anlon Healthcare IPO is a book-built issue aimed at raising capital for specific growth objectives. Here's a quick look at the core details of the offering:
- Issue Size: ₹121.03 Crore
- Fresh Issue: The entire issue is a fresh issue of 1.33 crore shares.
- Face Value: ₹10 per equity share
- Listing: BSE, NSE
Objectives of Anlon Healthcare IPO
The net proceeds from the fresh issue are intended to be utilized for:
- Funding capital expenditure for the proposed expansion of the manufacturing facility.
- Repayment or prepayment of certain outstanding secured borrowings.
- Meeting working capital requirements.
- General corporate purposes.
Anlon Healthcare IPO Date and Price
Mark your calendars! The subscription window for the Anlon Healthcare IPO is open for a limited period. Here are the important dates and the price band information:
Key Dates
| IPO Activity | Date |
|---|---|
| IPO Open Date | August 26, 2025 |
| IPO Close Date | August 29, 2025 |
| Basis of Allotment Finalization | September 1, 2025 (Tentative) |
| Initiation of Refunds | September 2, 2025 (Tentative) |
| Credit of Shares to Demat Account | September 2, 2025 (Tentative) |
| IPO Listing Date | September 3, 2025 (Tentative) |
Price and Lot Size
| Details | Information |
|---|---|
| Price Band | ₹86 to ₹91 per equity share |
| Minimum Lot Size (Retail) | 164 shares |
| Minimum Investment (Retail) | ₹14,924 (at the upper price band) |
Anlon Healthcare IPO GMP (Grey Market Premium)
The Grey Market Premium (GMP) is a crucial, though unofficial, metric that gives a glimpse into the market's sentiment towards an IPO before its official listing. The GMP for Anlon Healthcare IPO has been showing a positive trend, indicating that investors are expecting a healthy listing gain. It's important to remember that GMP is highly volatile and should not be the sole factor in your investment decision, but it does serve as a good indicator of demand. As of the latest reports, the GMP suggests a decent premium, which has generated significant interest among retail investors.
Anlon Healthcare IPO Allotment Status
After the IPO subscription window closes, the allotment process begins. The registrar for this issue is KFin Technologies Ltd., and they will be responsible for finalizing the basis of allotment. You can check your allotment status on the registrar's website, which is expected to be updated on September 1, 2025. You will need your PAN number, application number, or DP/Client ID to check the status. If you are a successful applicant, the shares will be credited to your demat account on September 2, 2025, and refunds will be initiated for those who did not receive an allotment.
Anlon Healthcare IPO Review and Financials
| Financial Year | Total Revenue | PAT | EBITDA |
|---|---|---|---|
| FY 2025 | 77.37 | 11.96 | 17.36 |
| FY 2024 | 66.69 | 9.66 | 15.46 |
| FY 2023 | 113.12 | 5.82 | 12.41 |
Anlon Healthcare has demonstrated a strong financial performance in recent years. The company has shown a remarkable increase in revenue and profit after tax (PAT), indicating robust growth. While there have been some fluctuations in revenue, the company's profitability has been consistently improving. The strategic use of the IPO proceeds for expansion and debt reduction is a positive sign, as it aims to strengthen the company's balance sheet and operational capacity. The company's competitive strengths include its diverse product portfolio, a focus on custom manufacturing, and a high-entry barrier due to long customer approval cycles. However, potential investors should also consider the risks, such as high customer concentration and a reliance on a single manufacturing facility.
Conclusion: Should You Apply?
The Grey Market Premium (GMP) is a crucial, though unofficial, metric that gives a glimpse into the market's sentiment towards an IPO before its official listing. The GMP for Anlon Healthcare IPO has been showing a positive trend, indicating that investors are expecting a healthy listing gain. As with any investment, it is advisable to conduct thorough due diligence and consult with a financial advisor before applying.
Disclaimer:
This post is for informational purposes only. Please do your own research before investing. IPO investments are subject to market risks.
Frequently Asked Questions (FAQs)
Anlon Healthcare Limited is a chemical manufacturing company that specializes in producing high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for use in formulations for human medicines, nutraceuticals, personal care, and veterinary products.
The IPO opens for subscription on August 26, 2025, and closes on August 29, 2025.
The price band has been fixed at ₹86 to ₹91 per equity share.
The minimum lot size is 164 shares, which translates to a minimum investment of ₹14,924 at the upper price band.
You can check your allotment status online on the registrar's website, KFin Technologies Ltd., after the basis of allotment is finalized on September 1, 2025.
The shares are expected to be listed on BSE and NSE on September 3, 2025 (tentative).
Anlon Healthcare has a strong business model and good financials, but it is subject to risks like market volatility and competition. It is recommended to conduct your own due diligence and consult with a financial advisor before making an investment decision.
0 Comments